{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-247658","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.587522+00:00","generated_at":"2026-05-17T02:33:10.781631+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Tango Therapeutics discloses $152.8M cash; provides vopimetostat clinical update","bullets":["Estimated cash, cash equivalents, and marketable securities of $152.8M as of Sept 30, 2025 (preliminary, unaudited).","Clinical slide presentation on ongoing Phase 1/2 trial of vopimetostat (TNG462) made available on Oct 23, 2025.","Cash estimate subject to completion of financial closing procedures and may change materially; auditor has not reviewed.","No full financial results or specific clinical data included in the disclosure."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-247658","json":"https://secwatch.observer/filing/0001193125-25-247658.json","markdown":"https://secwatch.observer/filing/0001193125-25-247658.md","text":"https://secwatch.observer/filing/0001193125-25-247658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312525247658/0001193125-25-247658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312525247658/d88744d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:33:10.781631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}